Aktuellt
SENASTE
OssDsign has decided to discontinue all operations related to Cranial PSI and focus solely on being an orthobiologics company. We update our estimates accordingly, removing all Cranial PSI sales from Q1/24, which impacts sales by -38% for 2024E and by -31% for 2025E. We reduce our opex assumptions and adjust the number of shares to reflect the directed share issue. This lowers our mid-point equity value to SEK 9 (12) per share.
LÄS MER
